Researchers from Fudan University (Shanghai, China) and collaborators tested the use of senescent tumor cell (STC)-derived nanovesicles to enable spatiotemporally confined immune responses for selective clearance of radiotherapy-induced STCs.
In a publication in Molecular Pharmaceutics, researchers from Fudan University Shanghai Cancer Center China present the design and construction of a positron emission tomography-computed tomography (PET-CT) molecular imaging probe that accurately targets PRMT5, enabling real-time dynamic visualization and quantitative detection of PRMT5 expression levels.
East China Normal University and Fudan University have jointly discovered tricyclic pyrimidine compounds acting as adenosine A2A and/or A2B receptor antagonists.
Researchers from Fudan University reported the development of CZL-077, a p300/CBP bromodomain inhibitor. p300 and CREB-binding protein (CBP) are closely related histone acetyltransferases that play central roles in regulating gene expression. Dysregulation of these proteins has been implicated in tumorigenesis and the development of therapy resistance.
Fudan University has described dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of bone disorders, immunological disorders, inflammatory disorders, viral infections and cancer.
Aging is marked by a gradual decline in body function, partly driven by the buildup of senescent cells. These cells stop dividing but release a mix of inflammatory and tissue-remodeling factors, known as the senescence-associated secretory phenotype (SASP).
Interferon (IFN)-α, on paper, should be quite effective against hepatocellular carcinoma, the most frequent form of primary liver cancer. IFN-α can suppress tumor growth directly by acting on tumor cells, as well as indirectly by activating cytotoxic CD8+ T cells. In addition, it can slow replication of hepatitis B virus, which is involved in 50% to 80% of cases of hepatocellular carcinoma. However, IFN-α on its own has performed disappointingly in clinical trials.
Researchers from Fudan University and their collaborators reported the synthesis and preclinical characterization of novel Bruton’s tyrosine kinase (BTK)-targeting proteolysis-targeting chimeras (PROTACs) based on ARQ-531, a potent, reversible, noncovalent BTK inhibitor.
Tumor necrosis factor-α (TNF-α) is a key cytokine involved in the pathogenesis of ulcerative colitis (UC), a chronic inflammatory bowel disease, and has emerged as a promising therapeutic target.
